Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy
- PMID: 33189597
- DOI: 10.1016/j.clgc.2020.10.004
Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy
Abstract
Nivolumab-ipilimumab has become the standard of care in the frontline setting for intermediate-/poor-risk metastatic renal cell carcinoma (mRCC). This regimen is associated with survival improvement but significant toxicity. Anti-programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1) monotherapy may provide response and offers a better safety profile. In this context, nivolumab-ipilimumab has been postulated as a rescue treatment after anti-PD-1/PD-L1 therapy. Recent retrospective data has shown positive results, and several nonrandomized clinical trials (NRCTs) have evaluated this strategy. Therefore, we performed a meta-analysis of available NRCTs to clarify the efficacy and safety of salvage nivolumab-ipilimumab in mRCC after prior anti-PD-1/PD-L1 monotherapy. We searched PubMed, Medline, Embase, and the Cochrane Central Register of Controlled Trials to identify clinical trials investigating the efficacy and safety of salvage nivolumab-ipilimumab after prior anti-PD-1/PD-L1 in patients with mRCC. Only phase II NRCTs were available for the analysis. The pooled effect of single proportions with a 95% confidence interval (CI) was used as the measure of effect (overall response rate [ORR] and incidence of grade ≥ 3 adverse events). Four studies accounting for 237 patients were included. All patients received prior anti-PD-1/PD-L1 monotherapy. The pooled ORR of salvage nivolumab-ipilimumab after prior anti-PD-1/PD-L1 failure was 10.0% (95% CI, 6%-14%; I2 = 41%; P = .17). The incidence of grade ≥ 3 irAEs was 27.0% (95% CI, 20%-35%; I2 = 0%; P = .56). The results of this analysis suggest that the use of salvage nivolumab-ipilimumab in mRCC after prior anti-PD-1/PD-L1 has limited activity with a 10% ORR, and a non-negligible toxicity with 1 of 4 patients developing grade ≥ 3 immune-related adverse events.
Keywords: Immune checkpoint blockade; Immunotherapy; Kidney cancer; Meta-analysis; Rechallenge.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.Cancer Med. 2022 Apr;11(7):1669-1677. doi: 10.1002/cam4.4587. Epub 2022 Feb 9. Cancer Med. 2022. PMID: 35138046 Free PMC article.
-
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).J Clin Oncol. 2022 Sep 1;40(25):2913-2923. doi: 10.1200/JCO.21.02938. Epub 2022 Apr 20. J Clin Oncol. 2022. PMID: 35442713 Free PMC article. Clinical Trial.
-
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.J Clin Oncol. 2020 Sep 20;38(27):3088-3094. doi: 10.1200/JCO.19.03315. Epub 2020 Jun 3. J Clin Oncol. 2020. PMID: 32491962 Free PMC article.
-
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.Eur Urol Oncol. 2021 Oct;4(5):755-765. doi: 10.1016/j.euo.2021.03.001. Epub 2021 Mar 20. Eur Urol Oncol. 2021. PMID: 33757737 Review.
-
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.Medicine (Baltimore). 2017 Jun;96(26):e7325. doi: 10.1097/MD.0000000000007325. Medicine (Baltimore). 2017. PMID: 28658143 Free PMC article. Review.
Cited by
-
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma.J Clin Med. 2024 Jan 5;13(2):307. doi: 10.3390/jcm13020307. J Clin Med. 2024. PMID: 38256441 Free PMC article. Review.
-
Immune-related risk prognostic model for clear cell renal cell carcinoma: Implications for immunotherapy.Medicine (Baltimore). 2023 Aug 25;102(34):e34786. doi: 10.1097/MD.0000000000034786. Medicine (Baltimore). 2023. PMID: 37653791 Free PMC article.
-
Current Status in Rechallenge of Immunotherapy.Int J Biol Sci. 2023 May 7;19(8):2428-2442. doi: 10.7150/ijbs.82776. eCollection 2023. Int J Biol Sci. 2023. PMID: 37215995 Free PMC article. Review.
-
Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis.Front Oncol. 2022 Dec 2;12:996553. doi: 10.3389/fonc.2022.996553. eCollection 2022. Front Oncol. 2022. PMID: 36531034 Free PMC article.
-
Overexpression of RAB34 associates with tumor aggressiveness and immune infiltration in glioma.Biosci Rep. 2022 Oct 28;42(10):BSR20212624. doi: 10.1042/BSR20212624. Biosci Rep. 2022. PMID: 36222286 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials